Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00277-022-04999-1.pdf
Reference25 articles.
1. Vogl DT, Dingli D, Cornell RF et al (2018) Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 36(9):859–866
2. Neupane K, Wahab A, Masood A et al (2021) Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of triple class refractory multiple myeloma. J Blood Med 12:529–550
3. Syed YY (2019) Selinexor: First Global Approval [Review]. Drugs 79(13):1485–1494
4. US-FDA. FDA grants accelerated approval to selinexor for multiple myeloma 2019 [cited 2022 01/14/2022]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-selinexor-multiple-myeloma
5. Bahlis NJ, Sutherland H, White D et al (2018) Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma [Journal: Article]. Blood 132(24):2546–2554
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis;Current Problems in Cancer;2024-06
2. A review of the mechanism of action, safety, and efficacy of selinexor in multiple myeloma;Canadian Hematology Today;2023-03-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3